Qulipta 60 mg/1 (Atogepant TABLET) 60 mg/1

Qulipta 60 mg is a medication used for preventive treatment of migraines. This oral tablet, manufactured by AbbVie Inc., is designed to help reduce the frequency of migraine episodes.

Strength

60 mg/1

Pack Size

4 TABLET in 1 BOTTLE (0074-7094-04)

Manufacturer / TM Owner

AbbVie Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Qulipta 60 mg is primarily used for the preventive treatment of migraines. It is designed to help reduce the number of migraine days a person experiences. This medication is not intended for the acute treatment of migraines but rather for long-term prevention. People often wonder, 'What is Qulipta used for?' and the answer is its role in migraine prevention.

Side Effects

Common effects of Qulipta 60 mg may include nausea, fatigue, and constipation. Some users might experience upper abdominal pain or vomiting. These effects can vary from person to person, and it's important to monitor how the body responds to the medication.

Precautions & Warnings

Qulipta 60 mg should be handled with care. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. This medication should be stored at room temperature and kept out of reach of children. Always inform your healthcare provider about any other medications you are taking.

Avoid Interactions

Qulipta 60 mg may interact with certain medications, including strong CYP3A4 inducers and inhibitors. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare professional, as it may affect the efficacy of the medication.

Frequently Asked Questions

Qulipta is used for the preventive treatment of migraines to reduce the frequency of migraine episodes.

Qulipta is taken orally, typically once daily, as directed by a healthcare professional.

Common side effects may include nausea, fatigue, constipation, upper abdominal pain, and vomiting.

It is important to discuss all current medications with a healthcare provider to avoid potential interactions.

Qulipta should be stored at room temperature and kept out of reach of children.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.